Business Context and Reporting Period
This Form 8-K Current Report was filed by NanoViricides, Inc. on May 28, 2013. The filing primarily addresses corporate governance changes, specifically the appointment of a new independent director and the finalization of compensation arrangements for the interim Chief Financial Officer.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, or cash flow data. However, it discloses specific financial commitments and prior capital transactions:
- Director Compensation: Annual fee of $30,000 for the new Board member, payable quarterly.
- CFO Compensation: Monthly cash compensation of $9,000 plus 9,000 shares of Series A Convertible Preferred Stock.
- Prior Debt Instrument: Reference to a $4,000,000 subscription for Unsecured 8% Coupon Series B Convertible Debentures by the new director on February 1, 2013.
Material Changes
The material changes reported in this period include:
- Board Appointment: Milton Boniuk, MD, was appointed as an independent member of the Board of Directors on May 28, 2013.
- Executive Compensation: Finalization of the compensation agreement for Meeta Vyas, Interim CFO, effective May 30, 2013.
Management Commentary, Risks, and Unusual Items
Management Commentary and Strategic Context:
- Dr. Boniuk is described as a renowned eye surgeon and long-term investor with expertise in ocular adenoviral infections, which is directly relevant to the Company's drug candidate for epidemic kerato-conjunctivitis (EKC).
- The Company notes that its EKC drug candidate was successfully tested in rabbits, which serve as a surrogate for the viral disease in human eyes.
Risks and Contingencies:
- Related Party Transaction: The Interim CFO, Meeta Vyas, is married to Anil Diwan, the President and Chairman of the Registrant.
- Concentration of Interest: The new director, Dr. Boniuk, holds a significant financial interest in the Company through the $4 million debenture subscription.
Investor Verification Checklist
- Verify the terms of the $4,000,000 Series B Convertible Debentures referenced in the February 1, 2013 filing.
- Confirm the valuation and conversion terms of the Series A Convertible Preferred Stock issued to the Interim CFO.
- Review the status of the EKC drug candidate and the timeline for human clinical trials following the successful rabbit testing.
- Assess the potential impact of the related-party relationship between the President/Chairman and the Interim CFO on financial oversight.